Read Larry Connors' blog – Short Term Trading Strategies
-- August 27, 2009 Crocs, Inc. (NASDAQ: CROX | Quote | Chart | News | PowerRating) trading at $6.49 on a volume of 1.37M shares.
In a press release out on August 27, 2009 Crocs, Inc. Goes Retro with Debut of New Footwear Collection
NIWOT, Colo., Aug 27, 2009 -- Known for bringing innovative footwear to market, Crocs, Inc. (NASDAQ: CROX | Quote | Chart | News | PowerRating) today announced its newest iconic style - the Crocband. The next generation of Crocs' celebrated Beach and Cayman styles, the Crocband Collection combines the very best features of Crocs original designs including world renowned comfort with the timeless appeal of retro sneakers.
About Crocs, Inc.
Crocs, Inc. is a designer, manufacturer and retailer of performance casual footwear for men, women and children under the Crocs(TM) brand.
All Crocs(TM) brand shoes feature Crocs' proprietary closed-cell resin, Croslite(TM), which represents a substantial innovation in footwear. The Croslite(TM) material enables Crocs to produce soft, comfortable, lightweight, superior-gripping, non-marking and odor-resistant shoes. These unique elements make Crocs(TM) footwear ideal for casual wear, as well as for professional and recreational uses such as boating, hiking, hospitality and gardening. The versatile use of the material has enabled Crocs to successfully market its products to a broad range of consumers.
Crocs(TM) shoes are sold in more than 120 countries and come in a wide array of colors and styles. Please visit www.crocs.com for additional information.
-- August 27, 2009 Mylan Inc. (Nasdaq: MYL | Quote | Chart | News | PowerRating) trading at $14.79 on a volume of 3.20M shares
In a press release on August 27, 2009 Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
PITTSBURGH, Aug 27, 2009 -- Mylan Inc. (Nasdaq: MYL | Quote | Chart | News | PowerRating) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of Sanofi Aventis' BenzaClin(R) to be approved by the U.S. Food and Drug Administration (FDA).
Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.
-- August 27, 2009 Omniture, Inc. (NASDAQ: OMTR | Quote | Chart | News | PowerRating) trading at $14.78 on a volume of 356,592 shares.
In a press release out on August 27, 2009 Omniture Launches CMO.com, a Strategic Resource for Today's Digital CMO
New Destination Provides One-Stop Resource for CMOs as They Shift to Digital Marketing
OREM, UT, Aug 27, 2009 -- Omniture, Inc. (NASDAQ: OMTR), a leading provider of online business optimization software, today announced the launch of CMO.com, a new Web site designed to provide CMOs with the insight and resources they need to lead marketing in a rapidly changing digital world.
About Omniture
Omniture, Inc. is a leading provider of online business optimization software, enabling customers to manage and enhance online, offline and multi-channel business initiatives. Omniture's software, which it hosts and delivers to its customers as an on-demand subscription service and on-premise solution, enables customers to capture, store and analyze information generated by their Web sites and other sources and to gain critical business insights into the performance and efficiency of marketing and sales initiatives and other business processes. In addition, Omniture offers a range of professional services that complement its online services, including implementation, best practices, consulting, customer support and user training through Omniture Education. Omniture's more than 5,000 customers include eBay, AOL, Wal-Mart, Gannett, Microsoft, Neiman Marcus, Oracle, Sony and HP. www.omniture.com
-- August 27, 2009 China Sunergy Co., Ltd. (Nasdaq: CSUN | Quote | Chart | News | PowerRating) last at $4.64 on a volume of 1.01M shares
In a press release out on August 27, 2009 China Sunergy Announces Financial Results for the Second Quarter Of 2009
Second Quarter Revenues of US$70.1 million; 41.5MW in Shipments Exceeds Guidance;--Gross Margin Improves to 9.7%; GAAP Net Income of $1.7 million
NANJING, China, Aug 27, 2009 -- China Sunergy Co., Ltd. (Nasdaq: CSUN), ("China Sunergy" or the "Company") a specialized solar cell manufacturer based in Nanjing, China, announced today its financial results for the second quarter of 2009.
About China Sunergy Co., Ltd.:
China Sunergy Co., Ltd. (NASDAQ: CSUN | Quote | Chart | News | PowerRating) ("China Sunergy") is a specialized manufacturer of solar cell products in China. China Sunergy manufactures solar cells from silicon wafers utilizing crystalline silicon solar cell technology to convert sunlight directly into electricity through a process known as the photovoltaic effect. China Sunergy sells solar cell products to Chinese and overseas module manufacturers and system integrators, who assemble solar cells into solar modules and solar power systems for use in various markets. For more information please visithttp://www.chinasunergy.com .
-- August 27, 2009 Orion Energy Systems Inc. (Nasdaq:OESX) trading at $3.17 on a volume of 15,684 shares.
In a press release out on August 27, 2009 Photo Release -- Orion Issued Patent for Its Energy-Efficient Modular Lighting Platform
Modular Design Makes Energy Saving Technology Installation, Maintenance Simple
MANITOWOC, Wis., Aug 27, 2009 -- Orion Energy Systems Inc. (Nasdaq:OESX) on Aug. 18 was awarded a patent from the U.S. Patent and Trademark office for the energy management company's energy efficient modular lighting platform. The patent was awarded for the modular features of the system, which make initial installation, and the integration of additional energy saving technologies, easy and affordable.
Orion Energy Systems Inc. (Nasdaq:OESX) is a leading power technology enterprise that designs, manufactures and implements energy management systems, consisting primarily of high-performance, energy-efficient lighting platforms, wireless controls systems and direct renewable solar technology for commercial and industrial customers without compromise. For more information, visit www.oesx.com.
-- August 27, 2009 ATS Medical, Inc. (Nasdaq: ATSI | Quote | Chart | News | PowerRating) trading at $2.79 on a volume of 1.60M shares
In a press release out on August 27, 2009 ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis
MINNEAPOLIS, Aug 27, 2009 -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced today that the FDA has approved a landmark clinical study in which cardiac surgeons will implant the ATS 3f(R) Aortic Bioprosthesis in a younger aortic valve replacement patient population that has not been previously studied in a controlled and scientific manner.
ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PicksThatMove.com e-mail: Info@picksthatmove.com WWW: http://www.picksthatmove.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
